Mobile

A TWO-ARM RANDOMIZED OPEN LABEL PHASE 2 STUDY OF CP-751,871 IN COMBINATION WITH EXEMESTANE VERSUS EXEMESTANE ALONE AS FIRST LINE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005573-21

A TWO-ARM RANDOMIZED OPEN LABEL PHASE 2 STUDY OF CP-751,871 IN COMBINATION WITH EXEMESTANE VERSUS EXEMESTANE ALONE AS FIRST LINE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the efficacy, in terms of progression free survival (PFS), of CP-751,871 in combination with exemestane versus exemestane alone as first line treatment for hormone-dependent advanced breast cancer in postmenopausal women.

Critère d'inclusion

  • Hormone receptor positive advanced breast cancer in postmenopausal women

Liens